Clinical Trials — Currently Recruiting (Australia)

Ask your doctor whether you or your child may be eligible for any of these trials.

1. 1.

   A Study of AZD0120 in Autoimmune Diseases

   Recruiting — Phase 1 — AstraZeneca

   https://clinicaltrials.gov/study/NCT07295847

2. 2.

   First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

   Recruiting — Phase 1 — Regeneron Pharmaceuticals

   https://clinicaltrials.gov/study/NCT06351592

3. 3.

   Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)

   Recruiting — Phase 3 — Stichting TRICALS Foundation

   https://clinicaltrials.gov/study/NCT06008249

4. 4.

   A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

   Recruiting — Phase 2 — Celgene

   https://clinicaltrials.gov/study/NCT06782490

5. 5.

   Sapu003 in Advanced mTOR-sensitive Solid Tumors

   Recruiting — Phase 1 — SAPU NANO (US) LLC

   https://clinicaltrials.gov/study/NCT07369505

6. 6.

   An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

   Recruiting — Phase 1 — Novartis Pharmaceuticals

   https://clinicaltrials.gov/study/NCT06617793

7. 7.

   Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

   Recruiting — Phase 1 — Novartis Pharmaceuticals

   https://clinicaltrials.gov/study/NCT06675864

8. 8.

   A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

   Recruiting — Phase 3 — Novartis Pharmaceuticals

   https://clinicaltrials.gov/study/NCT07225504

9. 9.

   A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

   Recruiting — Phase 2 — Hoffmann-La Roche

   https://clinicaltrials.gov/study/NCT07282574

10. 10.

    Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease

    Recruiting — Na — University of Melbourne

    https://clinicaltrials.gov/study/NCT05136222

11. 11.

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients

    Recruiting — Phase 1 — Vidya Therapeutics Inc

    https://clinicaltrials.gov/study/NCT07085507

12. 12.

    Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

    Recruiting — Phase 3 — Celgene

    https://clinicaltrials.gov/study/NCT06408259

13. 13.

    Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    Recruiting — Phase 3 — Novartis Pharmaceuticals

    https://clinicaltrials.gov/study/NCT06846281

14. 14.

    A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

    Recruiting — Phase 3 — Janssen Research & Development, LLC

    https://clinicaltrials.gov/study/NCT05702034

15. 15.

    An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

    Recruiting — Phase 1 — AstraZeneca

    https://clinicaltrials.gov/study/NCT07224373

16. 16.

    A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    Recruiting — Phase 2 — GlaxoSmithKline

    https://clinicaltrials.gov/study/NCT05878717

17. 17.

    Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

    Recruiting — Phase 2 — Novartis Pharmaceuticals

    https://clinicaltrials.gov/study/NCT06655896

18. 18.

    Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

    Recruiting — Phase 3 — Sanofi

    https://clinicaltrials.gov/study/NCT06141486

19. 19.

    A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

    Recruiting — Phase 3 — Janssen Research & Development, LLC

    https://clinicaltrials.gov/study/NCT05923073

20. 20.

    A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

    Recruiting — Phase 2 — ModernaTX, Inc.

    https://clinicaltrials.gov/study/NCT06735248

21. 21.

    Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

    Recruiting — Biogen

    https://clinicaltrials.gov/study/NCT05658497

22. 22.

    A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

    Recruiting — Phase 3 — Hoffmann-La Roche

    https://clinicaltrials.gov/study/NCT05271409

23. 23.

    A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.

    Recruiting — Phase 1 — Inventage Lab., Inc.

    https://clinicaltrials.gov/study/NCT05620940